Millennium, Structural GenomiX, Aventis deal

Structural will use its high throughput structural determination platform to support MLNM's selection and optimization of lead compounds. Structural will retain certain rights to use structural information of non-proprietary targets and may choose a validated drug target from MLNM's targets for its own drug discovery programs. MLNM will make an equity investment in Structural. ...